Abstract Letrozole, an aromatase inhibitor, is ineffective in the presence of ovarian estrogen production. Two subpopulations of apparently postmenopausal women might derive reduced benefit from letrozole due to residual or returning ovarian activity: younger women (who have the potential for residual subclinical ovarian estrogen production), and those with chemotherapy-induced menopause who may experience return of ovarian function. In these situations tamoxifen may be preferable to an aromatase inhibitor. Among 4,922 patients allocated to the monotherapy arms (5 years of letrozole or tamoxifen) in the BIG 1-98 trial we identified two relevant subpopulations: patients with potential residual ovarian function, defined as having natural menopause, treated without adjuvant or neoadjuvant chemotherapy and age B55 years (n = 641); and those with chemotherapy-induced menopause (n = 105). Neither of the subpopulations examined showed treatment effects differing from the trial population as a whole (interaction P values are 0.23 and 0.62, respectively). Indeed, both among the 641 patients aged B55 years with natural menopause and no chemotherapy (HR 0.77 [0.51, 1.16]) and among the 105 patients with chemotherapy-induced menopause (HR 0.51 [0.19, 1.39]), the disease-free survival (DFS) point estimate favoring letrozole was marginally more beneficial than in the trial as a whole (HR 0.84 [0.74, 0.95]). Contrary to our initial
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Introduction
Aromatase inhibitors (AI) are recommended for the adjuvant treatment of postmenopausal endocrine-responsive early breast cancer [1] and are now widely used in this setting globally. Letrozole, a third generation AI, exerts its clinical effect by reversibly inhibiting the aromatase enzyme thereby profoundly reducing estrogen levels in postmenopausal women. This enzyme in the cytochrome P-450 super family and the product of the CYP19 gene occurs in a number of tissues including subcutaneous fat, liver, muscle, brain, normal breast tissue, and mammary adenocarcinoma [2] . The aromatase enzyme is responsible for blocking the final step in the conversion of the adrenal androgen substrate androstenedione to estrogen in the peripheral tissues, the predominant source of estrogen in postmenopausal women. In this setting letrozole reduces estrogen production by more than 90% [3] .
However, in women whose ovaries are active, the temporary reduction in estradiol production caused by aromatase inhibition will increase gonadotrophin release and in turn stimulate follicular growth and further estrogen production, thus rendering letrozole and other AIs ineffective in this setting. Case reports suggest that this stimulatory effect on gonadotrophin production may induce ovarian activity and estrogen production in women with chemotherapy-induced amenorrhea or in those close to the menopausal transition [4, 5] . AIs have also been used therapeutically in premenopausal women to stimulate gonadotrophin production and ovulation for treatment of infertility [6, 7] .
The results of the BIG 1-98 clinical trial indicate that among postmenopausal women with endocrine-responsive early breast cancer adjuvant letrozole is superior to tamoxifen both in terms of disease-free survival (DFS) and overall survival [8] [9] [10] [11] . Patients eligible for BIG 1-98 met criteria for post-menopausal status, but were heterogeneous in that some of the patients had become postmenopausal as a result of chemotherapy and others had experienced a natural menopause at various periods prior to study entry.
We hypothesized that patients with chemotherapyinduced menopause and those with recent natural menopause without chemotherapy might derive reduced benefit from letrozole due to their potential for ovarian estrogen production. The current analysis therefore explores whether patients with chemotherapy-induced menopause and those with potential residual ovarian function, defined as aged less than or equal to 55 years with natural menopause who did not receive chemotherapy, derived lesser benefit from letrozole as compared to tamoxifen than was seen in the trial as a whole.
Methods
Breast International Group (BIG) study 1-98 is a Phase 3, double-blind randomized trial that evaluates the effect of the AI letrozole compared with tamoxifen. From March 1998 to May 2003, 8,010 postmenopausal women with hormone receptor-positive early breast cancer were randomized to one of the four following treatment arms: tamoxifen for 5 years, letrozole for 5 years, tamoxifen for 2 years followed by letrozole for 3 years, and letrozole for 2 years followed by tamoxifen for 3 years. Patients were enrolled in the two-arm randomization option of letrozole or tamoxifen from March 1998 to March 2000 and the four-arm option from April 1999 to May 2003. The current analysis focuses on the 4,922 patients who were randomized to the two monotherapy arms (two-and four-arm randomization options) at 76 months median follow-up [10, 11] .
The trial protocol did not dictate whether or not to give chemotherapy (adjuvant or neoadjuvant). The protocol allowed adjuvant and/or neoadjuvant chemotherapy, given prior to study entry or concurrently with the assigned endocrine therapy. In most cases chemotherapy was completed prior to study entry. Patients were evaluated for menopausal status at study entry. To be eligible patients had to be postmenopausal, age 45 years or older, and to fit into one of the following categories: any age with bilateral oophorectomy; radiation ovarian ablation with C3 months amenorrhea; hysterectomized patients either over 55 years or if \55 years with postmenopausal follicle stimulating hormone (FSH), luteinizing hormone (LH) and estradiol levels; for patients who did not receive HRT within 3 months of randomization, amenorrhea duration of [12 months for patients under 50 years or [6 months for those 50 years and over; for patients who received HRT within 3 months of randomization, HRT must have ceased for at least 1 month and if under 55 years must have had postmenopausal FSH, LH and estradiol levels. Patients who were not postmenopausal at the start of chemotherapy and completed C6 cycles cyclophosphamide, methotrexate and 5-fluorouracil (CMF) or C4 cycles doxorubicin and cyclophosphamide (AC) and age C45 and FSH, LH, and estradiol in postmenopausal range prior to randomization were eligible and defined as having had chemotherapyinduced menopause.
Two subpopulations of patients were analyzed: those with chemotherapy-induced menopause and those with potential residual ovarian function, defined as young (age B55 years) patients who had natural menopause without any chemotherapy. In the absence of data on date of last menses, the latter subpopulation was considered the most likely to have residual subclinical ovarian function.
The primary trial end point was DFS, defined as the time from randomization to the first of the following events: recurrence at local, regional, or distant sites; a new invasive cancer in the contralateral breast; any second (non-breast) malignancy; or death without a prior cancer event. Followup was censored at last disease assessment, or among patients randomized to receive 5 years of tamoxifen but who chose to crossover to letrozole (subsequent to the presentation of initial efficacy results favoring letrozole in 2005) was censored at the time of crossover [10] . Baseline characteristics were compared using two-sided Fisher's exact tests and two sample t tests. Treatment groups were compared via a stratified log-rank test of DFS, with randomization option (two-arm or four-arm) as a stratification factor, and Kaplan-Meier plots were generated. Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) stratified by randomization option; multivariable models were adjusted for age at randomization, local therapy received, tumor size, tumor grade, ER/PgR status (locally assessed), HER2 status (centrally assessed), nodal status, and presence of peritumoral vascular invasion. The interactions of treatment by subpopulation were tested by Cox proportional hazards models including treatment groups, an indicator of the subpopulation, and the interaction term.
For all patients who had natural menopause without chemotherapy, Subpopulation Treatment Effect Pattern Plot (STEPP) analysis [12] was used to investigate the pattern of difference in 5-year DFS between treatment arms according to patient age at randomization. Based on simulations, a P value for the interaction test of age and treatment was calculated.
Results
The BIG 1-98 trial included 4,922 postmenopausal patients with hormone-responsive early breast cancer who were randomized to the two monotherapy groups, 2,463 to letrozole and 2,459 to tamoxifen. Of them, 3,633 (73.8%) were classified as having natural menopause, treated without chemotherapy; 1,118 (22.7%) were classified as natural menopause treated with chemotherapy; and 105 (1.3%) were classified as chemotherapy-induced menopause (Table 1) . Of the patients with natural menopause treated without chemotherapy, 641 were age B55 years at randomization.
Chemotherapy-induced menopause
Of the 105 patients with chemotherapy-induced menopause, one was considered to have regained ovarian function and unblinding was requested. Thirteen of the patients reported vaginal bleeding (6 letrozole and 7 tamoxifen). However, data on return of menses was not routinely collected, and ovarian function was not monitored biochemically. Overall, the treatment groups were well-balanced with no statistically significant differences for any of the baseline characteristics ( Table 2 ). The mean age at randomization was 49 years in both treatment groups, ranging from 45 to 59 years. Seventeen (31.5%) of 54 patients randomized to the tamoxifen only arm crossed over to letrozole after at least 3 years of tamoxifen treatment. As would be expected among patients treated with CT chemotherapy, ER estrogen receptor, PgR progesterone receptor, RT radiotherapy, HER2 human epidermal growth factor receptor 2 chemotherapy, tumor characteristics were of higher risk than the overall population-with a statistically significant higher proportion of node positivity, grade 3 or [2 cm tumors. Kaplan-Meier plots of DFS in this subpopulation for letrozole and tamoxifen are shown in Fig. 1 Potential residual ovarian function (young patients who had natural menopause and no chemotherapy) Among the patients who experienced natural menopause, 641 were age B55 and did not receive any chemotherapy. In this subpopulation, the treatment groups were balanced with no statistically significant differences for most of the baseline characteristics examined, except for nodal status: more patients treated with letrozole were node negative (72.8%) compared to the patients treated with tamoxifen (66.0%) (P = 0.05; Table 2 ). Of the 321 patients in this subpopulation who were randomized to tamoxifen, 83 (25.9%) crossed over to letrozole after at least 3 years of tamoxifen treatment. This subpopulation of younger patients who had natural menopause and did not receive chemotherapy had a lower risk profile than the overall BIG 1-98 population with statistically significantly less node positivity and fewer grade 3 and [2 cm tumors.
Kaplan-Meier plots of DFS for letrozole and tamoxifen are given in Fig. 3 . As for chemotherapy-induced menopause patients, young natural menopause patients also appeared to derive greater benefit from letrozole than tamoxifen (HR 0.77 [0.51, 1.16 ], univariate Cox model), and the magnitude of the trend favoring letrozole was comparable to that in the entire monotherapy population (HR = 0.84, Fig. 2 ). The interaction of treatment effects and whether the patient was in this subgroup was not statistically significant (P = 0.62). A multivariate Cox model of DFS again favored patients who received letrozole (HR 0.79, [0.51, 1.22] ) in this subpopulation.
For all 3,633 patients who had natural menopause without chemotherapy, the STEPP analysis in Fig. 4 [10] , patients with chemotherapy-induced menopause, and patients with age B55 years old at randomization with natural menopause who received no chemotherapy. The box size is proportional to the inverse of the standard error of the hazard ratio estimates. The horizontal line gives the 95% confidence interval the treatment comparison across age (P = 0.67 for interaction).
Discussion
The analysis of two subgroups of BIG 1-98 presented here does not support the concern which motivated its conduct: that the benefit of letrozole over tamoxifen might be reduced or reversed following chemotherapy-induced menopause or in the early years following natural menopause without chemotherapy. Indeed in both the chemotherapy-induced menopause subpopulation (HR = 0.51) and in the young natural menopause group (HR = 0.77) the trend favoring letrozole over tamoxifen was numerically stronger than in the entire monotherapy population (HR = 0.84).
The patients in the chemotherapy-induced menopause subpopulation were selected to receive adjuvant chemotherapy and thus were, as would be expected, a higher risk population than the overall trial population. Higher risk patients in BIG 1-98 have been shown to benefit more from letrozole compared to tamoxifen than the lower risk patients [13] . It is therefore reassuring to note that this higher risk group did not lose benefit from letrozole by potential return of ovarian function.
Limitations of this analysis include the lack of specific collection of information on date of last menstrual period and the absence of definitive collection of incidence of return of ovarian function or of ovarian function monitoring. However, these results support the use of letrozole in patients meeting the menopausal status requirements for entry into BIG 1-98, including those experiencing chemotherapy-induced menopause and those with natural menopause who were B55 years at randomization.
Recovery of ovarian function following chemotherapyinduced menopause has been reported in between 9 and 43% [14] [15] [16] [17] [18] [19] [20] mainly among patients in their forties. Analysis of amenorrhea and return of menses in the IBCSG study VI population (in which patients received between 3 and 9 cycles of CMF) [20] indicated an incidence of amenorrhea of 18% in patients under 40, with a recovery rate of 43%, and an amenorrhea incidence of 74% and recovery rate of 9% in those 40 years and over, indicating a clear effect of age. Swain et al. [21] also reported results from 708 patients receiving 4 cycles of AC and 4 cycles of docetaxel in NSABP B30 indicating that for those who experienced chemotherapy-induced menopause (83%), recovery of menses by 24 months occurred in 45.3% aged under 40, 10.9% aged between 40 and 50 and in 3.2% of patients aged over 50.
Recovery of ovarian function can be delayed. The study of Abusief et al. [14] , which included 431 patients treated with doxorubicin and cyclophosphamide with or without paclitaxel demonstrated a chemotherapy-induced menopause rate of 72%, with recovery of ovarian function between 6 and 12 months following completion of chemotherapy in 14% and after more than 12 months in a further 3%. In the study of 145 patients by Minisini et al. [18] the median time to recovery was 8 months with an overall recovery rate of 35.3%.
CMF appears to be the most gonadotoxic regimen and it appears likely that the amount of cyclophosphamide received is the main determining factor for chemotherapyinduced menopause. In a recent further report of the Fig. 4 Subpopulation Treatment Effect Pattern Plots (STEPP) of 5-year disease-free survival (DFS) percents for letrozole vs. tamoxifen for overlapping subpopulations defined according to age at randomization for all 3633 patients with natural menopause who received no chemotherapy. The x-axis is the median age for overlapping subpopulations, each including approximately 300 patients. The P values, based on simulations, test for the interaction of age and treatment group NSABP B-30 results [22] , amenorrhea at 12 months was higher for cyclophosphamide containing regimens-69.8% for doxorubicin (D) and cyclophosphamide (C) followed by docetaxel (T), 57.7% for combination TAC and 37.9% for AT. Taxanes probably do not add to the rate of amenorrhea; in fact in the Minisini study [18] , patients receiving taxane had a statistically significant increase in chance of recovery of ovarian function.
Notwithstanding the limitations of data collection, patients in BIG 1-98 may have a lower rate of recovery of ovarian function than reported in these studies, presumably due in part to their older age (median 49; range 45-59), than that in most of the studies cited. An additional factor may be the strict definition for postmenopausal status which included biochemical testing for those with chemotherapy-induced menopause and for patients with potential residual ovarian function under 55 years [8] . The chemotherapy received was perhaps also a factor. 27.6% of the 105 chemotherapyinduced menopause patients received CMF, 62.9% received anthracycline plus cyclophosphamide regimens and 9.5% patients received CMF in combination with anthracycline.
Taking into consideration the observed recovery of ovarian function following chemotherapy-induced menopause and the possible stimulatory effect on ovarian function of AIs, caution has been advised with the use of AIs in patient populations where recovery is more likely [4, 16, 23, 24] , and guidelines have been suggested for monitoring ovarian function in patients starting AIs [25] . Clemons [24] suggests that biochemical monitoring is so unreliable that no patient with questionable ovarian function should receive an AI without some form of ovarian suppression for fear of missing optimal adjuvant benefit. However, the results presented here would suggest that this may be less of a concern clinically among patients meeting BIG 1-98 menopausal criteria. These results might not be generalizable to other patient groups in clinical practice. For example, this analysis of BIG 1-98 does not provide guidance for younger patients (under 45) with chemotherapy-induced menopause, as none were included in the population. Continued caution in AI use in these patients is required. For individual women, especially younger women with chemotherapy-induced menopause and selected patients close to the menopause transition, monitoring probably remains appropriate with serial blood tests for the first 12-24 months. Further research in this population also would seem warranted.
Recent review of outcomes for participants in the MA.17 trial of extended adjuvant letrozole [26] , who became postmenopausal following 5 years of adjuvant tamoxifen, has shown a very substantial benefit for extended adjuvant letrozole.
This finding and the results from the current analysis of BIG 1-98 indicate that women with recent cessation of ovarian function are candidates for treatment with AIs in most cases, and may potentially gain more than patients who are older and have a more established menopause. In conclusion, our results support the contention that among patients over 45 years who are either naturally postmenopausal or have become postmenopausal following chemotherapy, letrozole is likely to be effective. The incidence of recovery of ovarian function in this patient population is very low, though this possibility must always be considered to ensure appropriate endocrine adjuvant treatment for each individual patient.
